To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
Last action on Oct 28, 2025Referred to the House Committee on Education and Workforce.
Take Action
Summary
No summary available.
Lifecycle of the Bill
Introduced in House
Oct 28, 2025
Introduced in House
Oct 28, 2025
Referred to the House Committee on Education and Workforce.
Oct 28, 2025
